Key Stats for CVS Health Stock
- 52-Week Range: $59 to $98
- Current Price: $94
- Street Mean Target: $102
- Street High Target: $140
- Analyst Consensus: 18 Buys / 6 Outperforms / 4 Holds
- TIKR Model Target (Dec. 2030): $127
CVS Stock Posts Its Fifth Straight Beat as Aetna’s Medical Cost Recovery Gains Real Momentum
CVS Health Corporation (CVS) is one of the largest integrated health companies in the United States, combining a national retail pharmacy chain, Caremark (its pharmacy benefit manager), Aetna (its health insurance arm), and Oak Street Health (its primary care platform), and following Q1 2026 earnings reported May 6, the company posted its fifth consecutive quarterly beat with adjusted EPS of $2.57 against a consensus estimate of $2.20.
The single number that defines this quarter is Aetna’s medical benefit ratio of 84.6%.
Analysts had forecast that ratio, which measures the percentage of insurance premiums spent on medical services, at 88%, meaning CVS delivered nearly 300 basis points of outperformance on the metric that has been the central debate around CVS stock for nearly three years.
Revenue reached $100.4 billion, a 6% increase year over year and $5.3 billion ahead of the $95.1 billion consensus estimate, driven by an 11% revenue gain in Health Services and a 3% increase in Health Care Benefits.
CVS raised its full-year 2026 adjusted EPS guidance to $7.30 to $7.50, up from the prior range of $7 to $7.20, with the new midpoint sitting meaningfully above analysts’ pre-earnings estimate of $7.16.
CEO David Joyner said on the Q1 2026 earnings call: “We entered 2026 with strong momentum and our intentional execution and deliberate actions across CVS Health have led to another quarter of excellent performance.”
The Caremark pharmacy benefit manager segment delivered an 11% revenue gain but saw adjusted operating income fall around 7%, driven by continued pharmacy client price improvements as CVS transitions clients toward its TrueCost net-cost pricing model, a structural shift that compresses near-term PBM margins but strengthens long-term client retention.
One subsidiary exit adds clarity to the restructuring narrative: CVS’s Omnicare unit, the long-term care pharmacy business that filed for bankruptcy in September, received court approval May 13 for its $250 million sale to GenieRx Holdings, removing a distressed asset and allowing management to concentrate capital on Aetna’s recovery, Caremark’s repricing, and the Health100 platform launch planned for later in 2026.
Wall Street Lifts CVS Targets as the Aetna Earnings Recovery Becomes Undeniable
The thesis around CVS stock right now is not about whether the turnaround is real: five consecutive quarterly beats have answered that question.
The debate is about magnitude, specifically how far Aetna’s operating income can travel from its current recovery trajectory toward the company’s stated target margin by 2028, and whether Caremark’s near-term margin compression from the TrueCost transition will remain a drag or normalize as the pricing model becomes industry standard.
Wall Street’s current answer is cautiously bullish: 18 Buy ratings, 6 Outperforms, and 4 Holds, with a mean price target of around $102 implying around 8% upside from the current price of $94.18.
Bernstein raised its price target to $106 from $94 on May 12, reiterating an Outperform rating and citing Aetna recovery that is “proceeding effectively,” with the analyst adding that “we see Aetna earnings nearly doubling over the next 3 years as Medicare Advantage margins continue to normalize through disciplined pricing.”
The consensus EPS estimate for full-year 2026 now sits around $7 normalized on a per-share basis, with Q1’s $2.57 actual already running well ahead of the quarterly pace that the prior annual range implied, and forward estimates for Q2 2026 through Q2 2027 reflect a continued recovery trajectory in the $1.35 to $2.73 range per quarter.
EBITDA tells the same directional story: Q1 2026 came in at $5.82 billion, up 11.3% year over year, with the next several quarters expected to show sequential moderation before reaccelerating in early 2027 as Aetna’s Medicare Advantage repricing and benefit redesign for 2027 plans take full effect.
CVS Valuation Model Take
TIKR’s base case for CVS targets a stock price of around $127, implying around 35% total return over roughly 4 and a half years, anchored to a mid-case revenue CAGR of around 4% and an EPS growth CAGR of around 9%, both of which are grounded in Aetna’s demonstrated margin recovery and Caremark’s ongoing transition to net-cost pricing.
At $94 against a mid-case target of around $127 and a high-case target of around $215, with five consecutive quarterly beats already in the record and a raised full-year guide sitting above prior consensus, CVS stock appears undervalued on TIKR’s model, with the mid-case alone implying a compounding annual return of around 7%.
Is CVS Health stock a buy right now?
Wall Street has 18 Buy ratings and 6 Outperforms on CVS stock against just 4 Holds, with a mean price target of around $102 implying around 8% upside from $94.
TIKR’s base case targets around $127, implying around 35% total return over roughly 4 and a half years. The turnaround case is strengthening with five straight beats, but the key variable is whether Aetna’s medical benefit ratio holds near 85% into the more claims-intensive Q2 and Q3 periods.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
